Regeneron expands...

No wonder Regeneron is growing fast.

The expansion began several years ago when it launched its first successful drug, Eylea, which treats agerelated macular degeneration, a common loss of eyesight in older age.

But it also has a very promising new injectable drug on the market called Dupixent that treats eczema, a skin condition that causes severe itching and skin rashes.

During the second quarter of the year sales of Dupixent were $209 million, up from $28 million a year ago.

That may be one of the reasons why Regeneron is in a hurry to build a new manufacturing facility in East Greenbush as part of a $800 million second campus in the town. The Cuomo administration is offering Regeneron $140 million in incentives.